Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Spectinomycin hydrochloride
Drug ID BADD_D02064
Description An antibiotic produced by Streptomyces spectabilis. It is active against gram-negative bacteria and used for the treatment of gonorrhea.
Indications and Usage For use in the treatment of acute gonorrheal urethritis and proctitis in the male and acute gonorrheal cervicitis and proctitis in the female when due to susceptible strains of Neisseria gonorrhoeae.
Marketing Status approved; investigational; vet_approved
ATC Code J01XX04
DrugBank ID DB00919
KEGG ID D00869
MeSH ID D000198
PubChem ID 64769
TTD Drug ID D02PCR
NDC Product Code 66405-0003; 66603-818; 76321-0001; 55500-0006
UNII HWT06H303Z
Synonyms Spectinomycin | Actinospectacin | Prospec | Ferkel Spectam | Spectam, Ferkel | Kempi | Spectinomycin Dihydrochloride, Pentahydrate | Spectam | Spectinomycin Dihydrochloride, Anhydrous | Trobicin | Salmosan-T | Salmosan T | Stanilo | Spectinomycin Hydrochloride | Adspec
Chemical Information
Molecular Formula C14H25ClN2O7
CAS Registry Number 21736-83-4
SMILES CC1CC(=O)C2(C(O1)OC3C(C(C(C(C3O2)NC)O)NC)O)O.Cl
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Alanine aminotransferase increased13.03.04.005--
Anaphylactic reaction24.06.03.006; 10.01.07.001--
Anaphylactoid reaction24.06.03.007; 10.01.07.003--Not Available
Blood urea increased13.13.01.006--Not Available
Chills15.05.03.016; 08.01.09.001--
Creatinine renal clearance decreased13.13.01.013--Not Available
Dizziness02.11.04.006; 24.06.02.007; 17.02.05.003--
Haematocrit decreased13.01.05.001--Not Available
Haemoglobin decreased13.01.05.003--Not Available
Injection site pain12.07.03.011; 08.02.03.010--Not Available
Insomnia19.02.01.002; 17.15.03.002--
Nausea07.01.07.001--
Pyrexia08.05.02.003--
Urticaria23.04.02.001; 10.01.06.001--
Blood alkaline phosphatase increased13.04.02.004--
The 1th Page    1    Total 1 Pages